Raloxifene protects endothelial cell function against oxidative stress

British Journal of Pharmacology

Volumn 155, Issue 3, 2008, Pages 326-334

  Wong, C M ^a,b   Yung, L M ^a   Leung, F P ^a   Tsang, S Y ^a   Au, C L ^a   Chen, Z Y ^a   Yao, X ^a   Cheng, C H K ^a   Lau, C W ^a   Gollasch, M ^c   Huang, Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Endothelial dysfunction; Nitric oxide; Raloxifene; Reactive oxygen species

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLCHOLINE; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FULVESTRANT; HYDROGEN PEROXIDE; PROTEIN KINASE B; RALOXIFENE; REACTIVE OXYGEN METABOLITE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE RELAXATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; AORTA, THORACIC; CYCLIC GMP; ENDOTHELIAL CELLS; ESTROGEN ANTAGONISTS; ISOMETRIC CONTRACTION; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 52949136618     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.262     Document Type: Article

References (34)

1. Barrett-Connor E, Grady D, Sasheyi A, Anderson PW, Cox DA, Hoszowski K et al. (2002). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847-857.
2. Barrett-Connor E, Mosal L, Collins P, Geiger MJ, Grady D, Kornitzer M et al. (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355: 125-137.
3. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C (1997). Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circulation 96: 1964-1969.
4. Bolad I, Delafontaine P (2005). Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol 20: 270-274.
5. 2+ influx. J Pharmacol Exp Ther 312: 1266-1271.
6. Chan YC, Leung FP, Yao X, Lau CW, Vanhoutte PM, Huang Y (2007). Raloxifene modulates pulmonary vascular reactivity in spontaneously hypertensive rats. J Cardiovas Pharmacol 49: 355-361.
7. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G (2003). Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 88: 2135-2140.
8. Davignon J, Ganz P (2004). Role of endothelial dysfunction in atherosclerosis. Circulation 109: III-27-III-32.
9. Dowell FJ, Hamilton CA, McMurray J, Reid JL (1993). Effects of a xanthine oxidase/hypoxanthine free radical and reactive oxygen species generating system on endothelial function in New Zealand white rabbit aortic rings. J Cardiovasc Pharmacol 22: 792-797.
10. Félétou M, Vanhoutte PM (2006). Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 291: H985-H1002.
11. Fried R, Fried LW (1974). Xanthine oxidase (xanthine dehydrogenase). Bergmeyer (ed). In: Methods of Enzymatic Analysis, 2nd edn. Academic Press: New York. pp 644-649.
12. Goldfrank D, Haytoglu T, Frishman WH, Mohammad Z (1999). Raloxifene, a new selective estrogen receptor modulator. J Clin Pharmacol 39: 767-774.
13. Greenwald RA (1985). Handbook of Methods for Oxygen Radical Research. CRC Press: Florida, USA, pp 213-214.
14. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 42: 698-704.
15. Hisamoto K, Ohmichi M, Kanda Y, Adachi K, Nishio Y, Hayakawa J et al. (2001). Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 276: 47642-47649.
16. Houston M, Chumley P, Radi R, Rubbo H, Freeman BA (1998). Xanthine oxidase reaction with nitric oxide and proxynitrite. Arch Biochem Biophys 355: 1-8.
17. Jansson PJ, Asplund KUM, Makela JC, Lindqvist C, Nordstrom T (2003). Vitamin C (Ascorbic acid) induced hydroxyl radical formation in copper contaminated household drinking water: role of bicarbonate concentration. Free Radical Res 37: 901-905.
18. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL et al. (1997). Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 280: 146-153.
19. Kong LD, Zhang Y, Pan X, Tan RX, Cheng CHK (2000). Inhibition of xanthine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetiachinensis. Cell Mol Life Sci 57: 500-505.
20. Leung FP, Tsang SY, Yung LM, Wong CM, Chan YC, Leung HS et al. (2007a). Raloxifene, tamoxifen and vascular tone. Clin Exp Pharmacol Physiol 34: 809-813.
21. 2+ influx. Am J Physiol Renal Physiol 289: F137-F144.
22. Leung FP, Yung LM, Leung HS, Au CL, Yao X, Vanhoutte PM et al. (2007b). Therapeutic concentrations of raloxifene augments nitric oxide-dependent relaxation in porcine coronary artery. Br J Pharmacol 152: 223-229.
23. Leung HS, Seto SW, Kwan YW, Leung FP, Au ALS, Yung LM et al. (2007c). Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur J Pharmacol 555: 178-184.
24. McCord JM, Fridovich I (1969). Superoxide dismutase: an enzymic function for erythrocuprein. J Biol Chem 244: 6049-6055.
25. Mendelsohn ME, Karas RH (1999). The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
26. Quick KL, Hardt KI, Dugan LL (2000). Rapid microplate assay for superoxide scavenging efficiency. J Neurosci Methods 97: 139-144.
27. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F et al. (2001). Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21: 1512-1519.
28. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL (2003). Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 188: 304-309.
29. Shiojima I, Walsh K (2002). Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243-1250.
30. Simoncini T, Genazzani AR, Liao JK (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105: 1368-1373.
31. 2+ channels. Stroke 35: 1709-1714.
32. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K et al. (2002). Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105: 2083-2091.
33. Wong CM, Yao X, Au CL, Tsang SY, Fung KF, Laher I et al. (2005). Raloxifene prevents endothelial function in aging ovariectomized female rats. Vas Pharmacol 44: 290-298.
34. Yung LM, Leung FP, Yao X, Chen ZY, Huang Y (2006). Reactive oxygen species in vascular wall. Cardiovasc Hematol Disord Drug Targets 6: 1-19.